Divalproex Sodium Market Report 2026

Divalproex Sodium Market Overview

• Divalproex Sodium market size has reached to $1.96 billion in 2025 • Expected to grow to $2.76 billion in 2030 at a compound annual growth rate (CAGR) of 7% • Growth Driver: Rising Prevalence Of Neurological Disorders Fueling The Growth Of The Market Due To Increasing Epilepsy And Neurodegenerative Burden • Market Trend: Advances In Controlled-Release Therapies Enhance Treatment Convenience • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Divalproex Sodium Market?

Divalproex sodium is a prescription medication used to manage certain neurological and psychological conditions. It is made from a combination of sodium valproate and valproic acid, which work by increasing the levels of gamma aminobutyric acid (GABA), a chemical in the brain that helps reduce excessive nerve activity. By stabilizing electrical signals in the brain, this medication helps maintain mental and neurological balance. The main product types of divalproex sodium include tablets, capsules, extended-release tablets, and others. Tablets are solid oral dosage forms containing active ingredients, compressed into a defined shape for convenient administration. It can be administered through oral and intravenous routes and is applied for epilepsy treatment, bipolar disorder management, migraine prophylaxis, neuropsychiatric disorders, and others. It can be distributed through hospital pharmacies, retail pharmacies, online pharmacies, and others.

What Is The Divalproex Sodium Market Growth Forecast?

The divalproex sodium market size is expected to see strong growth in the next few years. It will grow to $2.76 billion in 2030 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to growth of neuropsychiatric disorders, demand for cost-effective generics, improved patient adherence formulations, expanded mental health awareness, broader healthcare access. Major trends in the forecast period include steady demand for neurological disorder management, growing use in bipolar disorder treatment, expansion of extended-release formulations, increased focus on generic drug availability, rising monitoring of drug safety and dosage optimization.

Global Divalproex Sodium Market Segmentation

1) By Product Type: Tablets, Capsules, Extended-Release Tablets, Other Products 2) By Route of Administration: Oral, Intravenous 3) By Application: Epilepsy Treatment, Bipolar Disorder Management, Migraine Prophylaxis, Neuropsychiatric Disorders, Other Applications 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distributions Subsegments: 1) By Tablets: 250 Mg Tablets, 500 Mg Tablets 2) By Capsules: 125 Mg Capsules, 250 Mg Capsules, 500 Mg Capsules 3) By Extended-Release Tablets: 250 Mg Extended-Release Tablets, 500 Mg Extended-Release Tablets 4) By Other Products: Oral Solution, Injectable Form

What Is The Driver Of The Divalproex Sodium Market?

The rising prevalence of neurological disorders is expected to fuel the growth of the divalproex sodium market going forward. Neurological disorders refer to conditions that affect the brain, spinal cord, or nerves, impairing function and causing symptoms such as muscle weakness, seizures, or cognitive issues. Increasing life expectancy is contributing to the rise in neurological disorders, as aging populations are more vulnerable to conditions such as Alzheimer’s and Parkinson’s that typically develop later in life. Divalproex Sodium is required for neurological disorders as it helps stabilize electrical activity in the brain, effectively preventing seizures and managing mood swings, which are common in conditions including epilepsy and bipolar disorder. For instance, in October 2023, according to the World Federation of Neurology (WFN), a UK-based international nonprofit neurological organization, more than 40% of the global population were living with a neurological condition, and the overall neurological disease burden was projected to nearly double by 2050. Therefore, the rising prevalence of neurological disorders is driving the growth of the divalproex sodium industry.

Key Players In The Global Divalproex Sodium Market

Major companies operating in the divalproex sodium market are AbbVie Inc., Sanofi S.A., Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., Aurobindo Pharma Limited, Hikma Pharmaceuticals Public Limited Company, Amneal Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Limited, Alembic Pharmaceuticals Limited, Supernus Pharmaceuticals Inc., Strides Pharma Science Limited, Upsher-Smith Laboratories LLC, Ajanta Pharma Limited, Ishita Active Pharmaceutical Ingredients, Varahi International, Roaq Chemicals Private Limited, MSN Laboratories Private Limited.

Global Divalproex Sodium Market Trends and Insights

Major companies operating in the divalproex sodium market are focusing on developing innovative solutions, such as delayed release capsule formulations, to improve patient-friendliness, reduce dosing frequency, and enhance tolerability compared to immediate-release tablets. A delayed release capsule is a formulation that releases the active ingredient (divalproex sodium) at a controlled rate, ensuring more stable blood levels and minimizing peak-dose side effects. For instance, in December 2024, Alembic Pharmaceuticals, an India-based generics company, received final approval from the US Food and Drug Administration (FDA) for its Divalproex Sodium Delayed Release Capsules USP, 125 mg. These capsules are therapeutically equivalent to the reference product, Depakote Sprinkle Capsules, and feature a sprinkle format that allows easier ingestion or administration, supporting improved patient adherence and overall treatment outcomes.

What Are Latest Mergers And Acquisitions In The Divalproex Sodium Market?

In June 2024, Lotus Pharmaceuticals, a Taiwan-based pharmaceutical company, acquired the Thailand business and commercial entity of Teva Pharmaceuticals for an undisclosed amount. Lotus will take over Teva Pharma Thailand's present product marketing and sales after the acquisition, and it will become a wholly owned subsidiary of Teva. Through the addition of respiratory and ophthalmic goods to its lineup and the expansion of its local staff to around 100 people, Lotus will be able to increase its footprint in Thailand and improve its reach through hospital and pharmacy channels. Teva Pharmaceuticals is an Israel-based manufacturer of divalproex sodium.

Regional Outlook

North America was the largest region in the divalproex sodium market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Divalproex Sodium Market?

The divalproex sodium market consists of sales of valproic acid oral solution, carbamazepine tablets, and lamotrigine tablets. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Divalproex Sodium Market Report 2026?

The divalproex sodium market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the divalproex sodium industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.